Highlights from

AAN 2019

American Academy of Neurology annual meeting

Philadelphia, USA 4-10 May 2019

Possibly lifesaving therapy in refractory PML

Transfer of anti-polyomavirus-specific T cells (PyVSTs) from healthy related donors is feasible and safe as adoptive immunotherapy of severely immunocompromised patients with refractory progressive multifocal leukoencephalopathy (PML). Encouraging results in 12 patients suggest PyVSTs could be a lifesaving therapy for patients who otherwise almost always die.

PML is an opportunistic infection of the central nervous system caused by activation of the JC polyomavirus (JCV) occurring in immunosuppressed patients. “Until now, there has been no treatment for PML, the diagnosis of which is almost like a death sentence for the patient”, explained Dr Erin Beck (National Institute of Health in Bethesda, USA).

“Basically, what we did was borrow immune cells from close relatives of the patients and make them active against the JVC”, Dr Beck described this form of adoptive immunotherapy. Her group used peptide libraries derived from BK Large T (LT) and Viral Protein 1 (VP1) that are highly cross-reactive with the structurally homologous JC proteins. PyVSTs were then generated from first-degree relatives of patients with refractory PML. Patients received 1x106 PyVST cells/kg, which could be followed by one or two additional infusions at 2x106 PyVSTs/kg, at minimal intervals of 28 days. The study's primary endpoint was safety.

Twelve subjects who received at least one infusion were included in the analysis. There were no serious treatment-related adverse events. Dr Beck was particularly relieved to see no cases of overt immune reconstitution inflammatory syndrome (IRIS), which can be fatal in itself. There were also no infusion reactions or graft vs host disease (GvHD). The therapy was also feasible; the importance of identifying 'good' donors and optimising the cell product was noted. Of 12 patients treated, 5 died and 7 survived. This suggests possible efficacy of PyVST as a lifesaving therapy. Dr Beck: “We did not expect them to do so well, since their condition was deteriorating even around the time of the first infusion. So, the results are very encouraging.” She could not say who benefitted the most from this therapy and which markers might predict survival

Cortese I, et al. AAN 2019, Plen01.002.

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.